| A blood atlas of COVID-19 defines hallmarks of disease severity and specificity DJ Ahern, Z Ai, M Ainsworth, C Allan, A Allcock, B Angus, MA Ansari, ... Cell 185 (5), 916-938. e58, 2022 | 161 | 2022 |
| Scc2 is a potent activator of cohesin’s ATPase that promotes loading by binding Scc1 without Pds5 NJ Petela, TG Gligoris, J Metson, BG Lee, M Voulgaris, B Hu, S Kikuchi, ... Molecular cell 70 (6), 1134-1148. e7, 2018 | 159 | 2018 |
| Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma B Hilvering, TSC Hinks, L Stöger, E Marchi, M Salimi, R Shrimanker, ... Mucosal immunology 11 (5), 1408-1419, 2018 | 63 | 2018 |
| Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients J Youngs, NM Provine, N Lim, HR Sharpe, A Amini, YL Chen, J Luo, ... PLoS Pathogens 17 (9), e1009804, 2021 | 44 | 2021 |
| Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function C Hardman, W Chen, J Luo, P Batty, YL Chen, J Nahler, Y Wu, ID Pavord, ... Journal of Allergy and Clinical Immunology 143 (6), 2329-2333, 2019 | 16 | 2019 |
| The roles of type 2 cytotoxic t cells in inflammation, tissue remodeling, and prostaglandin (pg) d2 production are attenuated by pgd2 receptor 2 antagonism W Chen, J Luo, Y Ye, R Hoyle, W Liu, R Borst, S Kazani, EA Shikatani, ... The Journal of Immunology 206 (11), 2714-2724, 2021 | 10 | 2021 |
| Neuromedin U promotes human type 2 immune responses Y Ye, J Luo, N Zeng, S Jiang, W Chen, RD Hoyle, P Klenerman, ... Mucosal Immunology 15 (5), 990-999, 2022 | 8 | 2022 |
| Multiple interactions between Scc1 and Scc2 activate cohesin’s DNA dependent ATPase and replace Pds5 during loading NJ Petela, TG Gligoris, J Metson, BG Lee, M Voulgaris, B Hu, S Kikuchi, ... bioRxiv, 205914, 2017 | 6 | 2017 |
| Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19 J Luo, YL Chen, W Chen, DA Duncan, A Mentzer, JC Knight, G Ogg, ... Allergy, Asthma & Clinical Immunology 17, 1-12, 2021 | 5 | 2021 |
| Fevipiprant Inhibits DP2Mediated Upregulation of Tissue Remodeling Genes and Autocrine Prostaglandin D2Production in Tc2 Cells L Xue, W Chen, Y Ye, E Shikatani, S Kazani, DA Sandham D69. ASTHMA SUBPHENOTYPES, TARGETS AND THERAPEUTICS, A7418-A7418, 2020 | 2 | 2020 |
| Fevipiprant antagonises prostaglandin D2-induced activation of type-2 CD8 T cells (Tc2) W Chen, R Borst, J Luo, MM Chizari, LC De Erauso, VJ Erpenbeck, ... European Respiratory Journal 54 (suppl 63), 2019 | 2 | 2019 |
| Correction: Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma B Hilvering, TSC Hinks, L Stöger, E Marchi, M Salimi, R Shrimanker, ... Mucosal Immunology 12 (2), 581, 2019 | 2 | 2019 |
| Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Potently Inhibits Chemotaxis and Cytokine Production by Group 2 Innate Lymphoid Cells L Xue, C Hardman, W Chen, P Batty, G Ogg, VJ Erpenbeck, DA Sandham C101. ASTHMA CLINICAL AND MECHANISTIC STUDIES, A5959-A5959, 2018 | 2 | 2018 |
| Type-2 CD8+ T lymphocytes responsive to PGD2 and LTE4 in severe eosinophilic asthma B Hilvering, TSC Hinks, L Stöger, E Marchi, M Salimi, R Shrimanker, ... bioRxiv, 247171, 2018 | 2 | 2018 |
| Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s) W Chen, C Hardman, P Batty, J Luo, Y Wu, L Xue, G Ogg, DA Sandham, ... European Respiratory Journal 52 (suppl 62), 2018 | 1 | 2018 |
| IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma J Luo, W Chen, W Liu, S Jiang, Y Ye, R Shrimanker, G Hynes, ... Mucosal Immunology, 2024 | | 2024 |
| Prostaglandin D2 drives tissue remodelling functions and prostaglandin D2 autocrine production in type 2 cytotoxic T cells W Chen, J Luo, Y Ye, R Hoyle, W Liu, R Borst, S Kazani, E Shikatani, ... The journal of immunology 206, 2714-2724, 2021 | | 2021 |
| FEVIPIPRANT ANTAGONIZES PROSTAGLANDIN D2-INDUCED ACTIVATION OF TYPE-2 CD8+ T CELLS (TC2) D Sandham, W Chen, Y Ye, R Borst, J Luo, M Chizari, L De Erauso, ... RESPIROLOGY 25, 123-123, 2020 | | 2020 |
| Fevipiprant inhibits prostaglandin D2 mediated activation of group 2 innate lymphoid cells (ILC2s) D Sandham, W Chen, C Hardman, J Luo, L Xue, G Ogg, V Erpenbeck Respirology 24, 105-105, 2019 | | 2019 |
| Type-2 CD8+ T lymphocytes responsive to PGD2/LTE4 in severe eosinophilic asthma T Hinks, B Hilvering, L Stoger, E Marchi, M Salimi, R Shrimanker, W Lu, ... European Respiratory Journal 52 (suppl 62), 2018 | | 2018 |
